RxDoctor Payments Data

David Vogel, MD

Vascular Surgery · Omaha, NENPI 1033159850

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.8%), other and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Endologix LLC at 50.1% of the total. Reporting peaked in 2021 at $12,978 and has fallen 71.6% since, to $3,681 in 2025. Among vascular surgery clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,110in general payments, 2019–2025

Across 226 payments — averaging $181.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$21K
  • Angiodynamics, Inc.$13K
  • Medtronic$4K
  • Boston Scientific$996
  • Terumo Medical Corporation$688
  • Bard Peripheral Vascular, Inc.$413
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$18,00044%
  • Food & beverage$10,19425%
  • Other$12,91731%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,110 in reported general payments places this provider in the 95th percentile of 35 vascular surgery providers in Nebraska.

See all vascular surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$1,442,378
Medicare patients
600
Services billed
3,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$5,722
ClopidogrelClopidogrel Bisulfate170$2,179
Cilostazol42$1,027
Omeprazole12$143

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →